Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004020583 - POLYNUCLEOTIDE PREDICTOR SET FOR IDENTIFYING PROTEIN TYROSINE KINASE MODULATORS

Publication Number WO/2004/020583
Publication Date 11.03.2004
International Application No. PCT/US2003/026491
International Filing Date 26.08.2003
Chapter 2 Demand Filed 11.03.2004
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12Q 1/6837
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6813Hybridisation assays
6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
6837using probe arrays or probe chips
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US] (AllExceptUS)
  • HUANG, Fei [CN]/[US] (UsOnly)
  • HAN, Xia [CN]/[US] (UsOnly)
  • REEVES, Karen, A. [JM]/[US] (UsOnly)
  • AMLER, Lucas [DE]/[US] (UsOnly)
  • FAIRCHILD, Craig, R. [US]/[US] (UsOnly)
  • LEE, Francis, Y. (UsOnly)
  • SHAW, Peter [GB]/[US] (UsOnly)
Inventors
  • HUANG, Fei
  • HAN, Xia
  • REEVES, Karen, A.
  • AMLER, Lucas
  • FAIRCHILD, Craig, R.
  • LEE, Francis, Y.
  • SHAW, Peter
Agents
  • D'AMICO, Stephen, C.
Priority Data
60/406,38527.08.2002US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) POLYNUCLEOTIDE PREDICTOR SET FOR IDENTIFYING PROTEIN TYROSINE KINASE MODULATORS
(FR) IDENTIFICATION DE POLYNUCLEOTIDES POUR PREDIRE L'ACTIVITE DE COMPOSES INTERAGISSANT AVEC ET/OU MODULANT DES PROTEINES TYROSINE KINASES ET/OU DES VOIES DE PROTEINES TYROSINE KINASES DANS DES CELLULES MAMMAIRES
Abstract
(EN)
The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.
(FR)
La présente invention concerne des polynucléotides qui se sont révélés être en corrélation avec la sensibilité ou la résistance intrinsèque relative de cellules, par exemple, de lignées cellulaires mammaires, par rapport à un traitement à l'aide de composés qui interagissent avec et modulent, par exemple, inhibent, des protéines tyrosine kinases, telles que, par exemple, des membres de la famille des Src de tyrosine kinases, par exemple, Src, Fgr, Fyn, Yes, Blk, Hck, Lck et Lyn, ainsi que d'autres protéines tyrosine kinases, notamment, des récepteurs de Bcr-abl, de Jak, de PDGFR, de c-kit et d'Eph. Lesdits polynucléotides se sont avérés, par un programme de validation croisée à vote pondéré, présenter une utilité dans la prévision de la résistance et de la sensibilité de lignées cellulaires mammaires auxdits composés. Le niveau d'expression ou l'état de phosphorylation de certains polynucléotides est régulé par traitement à l'aide d'un composé inhibiteur de protéines tyrosine kinases particulier, indiquant ainsi que lesdits polynucléotides sont impliqués dans la voie de transduction du signal de protéines tyrosine kinases, par exemple, de la Src tyrosine kinase. Lesdits polynucléotides, dont les niveaux d'expression sont fortement corrélés avec la sensibilité ou la résistance aux médicaments et qui sont modulés par un traitement à l'aide des composés, comprennent des ensembles de prédicteurs ou de marqueurs de polynucléotides utiles dans des méthodes de prédiction de réponse médicamenteuse, et en tant qu'indicateurs de pronostic ou de diagnostic dans la gestion thérapeutique, notamment dans des domaines de maladies, par exemple le cancer du sein, dans lesquels la signalisation par la voie des protéines tyrosine kinases, telle que la voie de la Src tyrosine kinase, est impliquée dans le processus de la maladie.
Also published as
Latest bibliographic data on file with the International Bureau